Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Moodys
Chubb
Citi
Covington
Queensland Health
Federal Trade Commission
Boehringer Ingelheim
QuintilesIMS

Generated: June 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,816,396

« Back to Dashboard

Summary for Patent: 7,816,396
Title:Method for increasing the bioavailability of glycopyrrolate
Abstract:The invention relates to a method of treating sialorrhea in a human patient, which comprises orally administering glycopyrrolate in a liquid solution to the human patient under fasted conditions.
Inventor(s): Roberts; Alan (Woodstock, GA), Venkataraman; Balaji (Alpharetta, GA)
Assignee: Shionogi Pharma, Inc. (Atlanta, GA)
Application Number:12/648,068
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,816,396
Patent Claims: 1. A method of treating sialorrhea in a human patient, which comprises orally administering about 1 mg to about 10 mg of glycopyrrolate in a liquid solution to the human patient under fasted conditions, wherein the ratio of the extent of absorption of glycopyrrolate at t=.infin. (AUC.sub.0-.infin.) following administration without food to AUC.sub.0-.infin. following administration with food is greater than 1.8, and wherein the patient has not consumed food during the period from 30 minutes prior to the administration of glycopyrrolate to 1 hour after the administration of glycopyrrolate.

2. The method of claim 1, wherein the AUC.sub.0-.infin. following administration under fasted conditions is greater than 1.0 ng*hr/mL.

3. The method of claim 1, wherein the AUC.sub.0-.infin. following administration under fasted conditions is greater than 1.7 ng*hr/mL.

4. A method of treating sialorrhea in a human patient, which comprises orally administering about 1 mg to about 10 mg of glycopyrrolate in a liquid solution to the human patient under fasted conditions, wherein the administration of glycopyrrolate under fasted conditions results in an increase of the maximum plasma concentration (C.sub.max) and the extent of absorption of glycopyrrolate at t=24 hours (AUC.sub.0-24 hrs) as compared to the administration of glycopyrrolate under fed conditions, wherein the ratio of C.sub.max following administration without food to C.sub.max following administration with food is greater than 1.1, wherein the ratio of AUC.sub.0-24 hrs following administration without food to AUC.sub.0-24 hrs following administration with food is greater than 1.8, wherein the AUC.sub.0-24 hrs following administration under fasted conditions is greater than 1.0 ng*hr/mL, and wherein the patient has not consumed food during the period from 30 minutes prior to the administration of glycopyrrolate to 1 hour after the administration of glycopyrrolate.

5. The method of claim 4, wherein the AUC.sub.0-24 hrs following administration under fasted conditions is greater than 1.7 ng*hr/mL.

6. The method of claim 4, wherein the ratio of the extent of absorption of glycopyrrolate at t=.infin. (AUC.sub.0-.infin.) following administration without food to AUC.sub.0-.infin. following administration with food is greater than 1.8.

7. The method of claim 6, wherein the extent of absorption of glycopyrrolate at t=.infin. (AUC.sub.0-.infin.) following administration under fasted conditions is greater than 1.0 ng*hr/mL.

8. The method of claim 7, wherein the AUC.sub.0-.infin. following administration under fasted conditions is greater than 1.7 ng*hr/mL.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Harvard Business School
McKesson
US Army
Mallinckrodt
Queensland Health
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.